[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Turbett Surgical, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":55},{"warningLetters":4,"total":54},[5,31],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},746,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-07-29T04:00:00Z\">07\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-21T04:00:00Z\">07\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonkos-surgical-inc-712573-07212025\">Onkos Surgical, Inc. \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick J. Treacy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Onkos Surgical, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>77 E Halsey Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Parsippany\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ptreacy@onkossurgical.com\"> ptreacy@onkossurgical.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 712573\u003C\u002Fp>\u003Cp>July 21, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Patrick J. Treacy:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Parsippany, NJ from February 4, 2025 through April 4, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the ELEOS Limb Salvage System indicated for use in total hip and knee arthroplasty for reduction or relief of pain and\u002For improved hip function in skeletally mature patients with select conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Len Tokish, Vice President of Quality Assurance and Regulatory Affairs dated May 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to adequately implement the “Approved Supplier List” section of your “Supplier, Purchasing and Inspection Controls” procedure (SOP-013; Rev. 0-6; Effective: 4\u002F25\u002F16 - 2\u002F3\u002F25) which requires that you “\u003Cem>ensure compliance to ISO 13485\u003C\u002Fem>” for your Tier 1 suppliers as a “method of control” over approved suppliers. For example, you did not ensure compliance to the process validation requirements (clause 7.5.6) of ISO 13485 (Medical Devices – Quality Management Systems – Requirements for regulatory purposes) for the following three (3) Tier 1 suppliers in that you failed to adequately assess and\u002For document an assessment of the acceptability of their cleaning validations meant to demonstrate that in-process or final cleaning of your ELEOS Implant Devices and Instruments consistently meet your specifications for cleanliness:\u003C\u002Fp>\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Tier \u003Cstrong>(b)(4)\u003C\u002Fstrong> Final Cleaner of ELEOS Implant Devices\u003C\u002Fp>\u003Cp>i. You approved the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validation test report TR-2771D-01 (Rev. 1-2; Approved: 1\u002F24\u002F19 and 9\u002F10\u002F21) from this supplier despite it failing to define the maximum allowable devices per gallon per run, as required by section 9.2 of the corresponding test protocol TP-2771D-01 (Rev. 2; Approved: 9\u002F10\u002F21) which states “***\u003Cem>The main cleaning parameters that can impact the efficacy of the cleaning process include ***Quantity of parts\u003C\u002Fem> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>)***.”\u003C\u002Fp>\u003Cp>Similarly, you approved \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validation test report TR-2771E-01 (Rev. 1; Approved: 3\u002F18\u002F19) from this supplier despite it failing to document the maximum allowable quantity of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> per run, as required by sections 9.3, 9.4, and 9.5 of the corresponding test protocol TP-2771E-01 (Rev. 1; Approved: 8\u002F28\u002F18) which state “***\u003Cem>To validate the cleaning process, parts shall be cleaned using\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>over\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>runs***To create a\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>batch of product***Clean what is expected to be a\u003C\u002Fem> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” load in \u003Cstrong>(b)(4)\u003C\u002Fstrong>***\u003Cem>A cleaning process should not alter the appearance of parts or cause damage. If applicable, appropriate fixtures to hold the components during cleaning should be included in the study and used in routine production\u003C\u002Fem>***.”\u003C\u002Fp>\u003Cp>ii. You failed to adequately assess differences in product design and geometrical configurations of candidate devices for the adoption into device families of existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validations conducted by this supplier because you did not accurately answer guiding questions contained in your “\u003Cem>Assessment of Product Change or New Product Adoption for Cleaning Processes\u003C\u002Fem>” reports. For example:\u003C\u002Fp>\u003Cp> The AC-2772-01 (Rev. 01; Effective: 7\u002F25\u002F19) and AC-277D-01 (Rev. 2; Effective: 2\u002F26\u002F21) reports show that you failed to document rationale to support your answers of “no” to the question posed in section 2 – “\u003Cem>In relation to the existing product, does the candidate product have a similar or less complex design?\u003C\u002Fem>” – despite the candidate devices having 4 grooves, a drive, or a male thread compared to the worst-case and comparison devices, which have none of these features.\u003C\u002Fp>\u003Cp> The AC-2772-02 report (Rev. 1; Effective: 3\u002F23\u002F20) shows that you incorrectly answered “no” to the question posed in section 2 – “\u003Cem>In relation to the existing product, does the candidate product have fewer\u002Fsmaller or equivalent cannulated portions or lumens?\u003C\u002Fem>” – when you compared the candidate device (segmental proximal femur, PF-2000L-02M), which has 7 cannulated holes, to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> device (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and comparison devices (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), which contain no holes.\u003C\u002Fp>\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – Tier 1 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Implant Devices\u003C\u002Fp>\u003Cp>Although requested during the inspection, your Vice President of Quality Affairs and Regulatory Affairs was unable to provide documentation that you assessed the adequacy of the cleaning validations conducted in 2009 by this supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In reviewing the “Process Validation of***\u003Cstrong>(b)(4)\u003C\u002Fstrong> Clean Line” Operational Qualification (OQ) (E118-2116; Rev. 1; Approved: 1\u002F9\u002F09) and Performance Qualification (PQ) (E118-2116; Rev. 1; Approved: 2\u002F3\u002F09), the following deficiencies were observed:\u003C\u002Fp>\u003Cp>i. The rationale in the PQ report to accept deviations from the nominal operating range of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F) because OQ data showed that the process monitoring, total organic carbon (TOC), and gravimetric produced acceptable results at worst-case conditions for temperatures as low as \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F and control charts indicated a lower control limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (Deviation 3) does not take into account the vast differences in sample sizes (\u003Cstrong>(b)(4)\u003C\u002Fstrong> vs. \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and acceptance criterion (Ppk \u003Cstrong>(b)(4)\u003C\u002Fstrong> vs. Ppk \u003Cstrong>(b)(4)\u003C\u002Fstrong>) between PQ and OQ for the same tests (TOC and gravimetric analysis) such that passing results for parameters established during OQ are not transferrable to PQ.\u003C\u002Fp>\u003Cp>ii. This supplier failed to document rationale in the OQ and PQ reports for why it was acceptable to convert all negative values measured for the corrected “\u003Cem>mass recovered from gravimetric\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> and corrected “\u003Cem>mass recovered from\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> to 0.00 mg in the “\u003Cem>Gravimetric Extraction Summary\u003C\u002Fem>” table during gravimetric testing, thereby passing the acceptance criteria of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002Fcm\u003Csup>2\u003C\u002Fsup> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). For example, during OQ, an \u003Cstrong>(b)(4)\u003C\u002Fstrong> value as high as -1.59 mg for “Hip – 4” was converted to 0.00 mg without an explanation that accounts for the possibility of testing errors, inadequate test methodology (e.g., lack of sensitivity of testing methods), and uncalibrated state of measuring equipment.\u003C\u002Fp>\u003Cp>c. \u003Cstrong>(b)(4)\u003C\u002Fstrong> – \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Implant Devices &amp; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaner of ELEOS Instruments\u003C\u002Fp>\u003Cp>You approved the adoption of new products into this supplier’s existing \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning validations titled “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning Equipment &amp; Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) and “Zenith Final Ultrasonic Cleaning Equipment &amp; Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) per your Cleaning, Assembly, Packaging and Sterility (CAPS) Checklists for Project # 16-001 (Approved 10\u002F2\u002F24) and Project # 16-003 (Approved 4\u002F19\u002F24) referencing memo “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning” (2\u002F14\u002F19) and results of a 3rd party audit conducted 2\u002F23\u002F18 despite the following deficiencies:\u003C\u002Fp>\u003Cp>i. The OQ and PQ protocols failed to require documentation of the load configurations for all work orders in that the Vice President of Quality Affairs and Regulatory Affairs was not able to determine if devices were put in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> or broken up into \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>ii. The PQ protocol failed to include documentation of valid statistical rationale for cytotoxicity, endotoxin, and\u002For particulate testing. For example, the quantity tested per work order (66672, 66921, 66922) for cytotoxicity and endotoxin was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> respectively and the quantity tested per work order (66675, 66919, 66920) for cytotoxicity, endotoxin, and particulate was \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The immediate correction is to impose heightened controls at each supplier commensurate with risk until new worst-case cleaning validations can be completed that addresses each of the observed deficiencies for \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 1\u002F15\u002F26, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (target date not provided), and \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 3\u002F1\u002F26 at the latest.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an assessment of worst-case part justification by family was completed to establish new limits placed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You plan to add this new loading criteria to the final DHR review by 7\u002F15\u002F25. In addition, you plan to require an update to \u003Cstrong>(b)(4)\u003C\u002Fstrong> internal procedure to include predicate cleaning validation review by 7\u002F15\u002F25. Based on the results of the new cleaning validation, you plan to revise top level procedures by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an assessment of worst-case part justification was conducted and monitoring was put in place to control product release by assessing endotoxicity and cytotoxicity on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> basis. In addition, you plan to require an update to this supplier’s internal procedures to improve notification of triggers to their customers by 7\u002F1\u002F25.\u003C\u002Fp>\u003Cp>For \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you plan to conduct an assessment for worst-case part challenge per part family by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For all instruments, interim clean line controls were implemented to require shipment of instruments to your firm and analyses of those instruments, which includes worst-case part and part family assessments prior to adoption into your clean-line part family. All parts successfully assessed will then be cleaned using your validated clean line prior to release for commercial distribution. All implants will continue to be shipped to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning and will fall under controls established for therein.\u003C\u002Fp>\u003Cp>Corrective actions include updating your supplier control and design control procedures to establish minimum requirements for cleaning validations of implants and instruments, including defining key product attributes to consider when forming product families and what considerations trigger a new worst-case within a product family or new product cleaning family; creation of a procedure for part families and worst-case parts per family which defines and evaluates implant and instrument cleaning families to facilitate consistent assessment of device cleaning families across products; determination and justification of minimum sample size and attributes (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) for validations; development of a cleaning validation checklist and modification of a supplier audit checklist that captures the aforementioned worst-case part determination, sample sizes, and minimum attributes that will be used during supplier assessment as part of design transfer and new supplier onboarding, manufacturing transfer, and supplier audit; and periodic review of validations on a scheduled interval against new standards and requirements by 6\u002F15\u002F25.\u003C\u002Fp>\u003Cp>However, no target date was provided for the new cleaning validation planned for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, please provide a response regarding how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your Post Market Surveillance procedure (QP-18-004; Rev. 3; Effective: 6\u002F30\u002F22) which requires opening a CAPA when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis of infection complaints “***\u003Cem>is more than\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>above the literature rate or\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>are above the literature rate\u003C\u002Fem>***” for a given procedure type. For example, you did not initiate CAPAs when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> analysis for infection complaints exceeded the rates of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for the distal femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong>); \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for proximal femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>); and \u003Cstrong>(b)(4)\u003C\u002Fstrong>% for total femur (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) established in the journal article by Henderson et. al “\u003Cem>Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review\u003C\u002Fem>” (Journal Bone and Joint Surgery 2011) by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. Under CAPA 24-011 which was initiated on 9\u002F11\u002F24 to create a more robust methodology for trending and analyzing infection related complaints, you conducted a revised retrospective assessment of \u003Cstrong>(b)(4)\u003C\u002Fstrong> infection rates from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> (TM-25-0002; Rev. B; Approved 5\u002F14\u002F25) based on additional literature data to support updated baseline infection rates by procedure type. As a part of the corrective action, you plan to create new work instructions with requirements to perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> trend reporting for infections and \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> trend reports for all other postmarket surveillance key performance indicators (KPIs); revise management review presentation slides and quality planning, postmarket surveillance, complaint handling, and CAPA procedures; and provide training on the new procedures. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure to adequately establish and maintain procedures for validating the device design with regards to risk analysis, as required by 21 CFR 820.30(g).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 5.9 of your “Risk Management Process” procedure (SOP-008; Rev. 4-5; Effective: 3\u002F22\u002F23 - 1\u002F17\u002F25) which requires postmarket re-evaluation of risk management for a medical device as well as monitoring of postmarket information “***\u003Cem>for assurance that no unacceptable or previously unrecognized failure modes occur. In the event of such an occurrence the potential that the residual risk or its acceptability has changed and the impact on the previously implemented risk control measures shall be evaluated\u003C\u002Fem>***.” For example, you failed to utilize the real rate of occurrence for loosening in complaints PCR 11272023-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), PCR 05132024-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>), and PCR 10172024-1 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) calculated at 3.27%, 0.149%, and 3.1%, respectively, to evaluate the need to update the occurrence rating in the corresponding ELEOS Stem Implant Risk Table (Project # 16-001\u002F16-003; Rev. E; Approved: 4\u002F1\u002F19), which remains unchanged at \u003Cstrong>(b)(4)\u003C\u002Fstrong>% through \u003Cstrong>(b)(4)\u003C\u002Fstrong>% since April 1, 2019.\u003C\u002Fp>\u003Cp>An update to the postmarket rate of occurrence changes the failure mode from an acceptable risk to a conditionally acceptable risk, thereby requiring an evaluation for the need for additional risk controls and assessment for the acceptability of the residual risk as required under sections 5.6 and 5.7 of SOP-008.\u003C\u002Fp>\u003Cp>The adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. The immediate correction is to evaluate literature, sources, historical data, and\u002For engineering estimates against postmarket data and update the occurrence rates for the hazardous situations associated with the ELEOS Limb Salvage system by \u003Cstrong>(b)(4)\u003C\u002Fstrong> followed by a revision of the corresponding risk tables by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As a part of the corrective action, you plan to revise SOP-008 to ensure that the methods used to create and maintain risk assessment tables are well-defined and create work instructions for conducting risk assessments utilizing postmarket information by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Specifically, you failed to implement section 1.1 of your “Sample Size and Statistical Techniques” procedure (SOP-014; Rev. 2-4; Effective: 8\u002F16\u002F18 - 3\u002F22\u002F23) which “***\u003Cem>identifies valid statistical techniques that are used to establish, control and verify the acceptability of process capability and product characteristics***” pertaining to “***inspections and other analyses of objective data\u003C\u002Fem>***” of ELEOS Implant Devices received from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. during incoming inspections. For example, your Vice President of Quality Affairs and Regulatory Affairs acknowledged that the sampling plans of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sampled incoming device history records (DHRs) from this supplier were not traceable to a documented valid statistical rationale.\u003C\u002Fp>\u003Cp>a. You reviewed and approved incoming DHRs for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> on 11\u002F2\u002F20 and 11\u002F29\u002F21 where a sampling plan of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was used to inspect critical features during in-process inspections for which there is no documented rationale for use of this sampling plan. For example, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Tibial Baseplate Component, Size 4 (Part # TB-2204E-01M) Implant Devices, the line profile (curve) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> each were inspected against a specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Similarly, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Collar, 28 Diameter, Round, Porous, HA Treated (Part # HB-2800R-03M) Implant Devices, the diameter for \u003Cstrong>(b)(4)\u003C\u002Fstrong> each was inspected against a specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>b. You reviewed and approved incoming DHRs (Lot #: \u003Cstrong>(b)(4)\u003C\u002Fstrong>) where sampling plans utilized an AQL (acceptable quality limit) of \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> to inspect features during in-process and final inspections for which there are no documented rationales for use of these sampling plans. For example, out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> ELEOS Segmental Proximal Femur, Plasma Spray, Left 98 MM (Part # PF-2000L-02M) Implant Devices, the dimensional specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was inspected at an AQL level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> during final inspection on 1\u002F23\u002F24.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. The immediate corrections are to use a checklist to reassess and document rationales for acceptability of the existing AQLs selected for all contract manufactured ELEOS part families from 1\u002F1\u002F21 to 4\u002F1\u002F25 and share the rationales with the contract manufacturers by 11\u002F21\u002F25 and update SCAR 25-01 to require the contract manufacturer to include documented evidence for all inspected dimensions and associated AQL quantities by 5\u002F14\u002F25. As a part of the corrective actions, you plan to update SOP-014 and WI-013-31 (Incoming Inspection Process) to require review of incoming inspection results, consolidation of sampling procedures, set up traceable valid statistical rationales, and confirm AQLs by 7\u002F6\u002F25; update SOP-007 (Design Control) and various design transfer, manufacturing transfer, supplier, and incoming inspection checklists to include instructions for the acceptance of a supplier’s sampling procedure with confirmation of conformance to those procedures during incoming inspection of supplier DHRs by \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and develop \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection requirement checklists for all suppliers with a sampling procedure traceable to a valid statistical rationale based on \u003Cstrong>(b)(4)\u003C\u002Fstrong> by 7\u002F18\u002F25. However, these corrections and\u002For corrective actions only address the need to have a statistically valid rationale for the use of sampling plans which follow AQL and not sampling plans which utilize inspections of select critical features for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> devices. Therefore, please provide a response on how you plan to address the above deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s ELEOS Limb Salvage System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure to submit a medical device Report of Correction or Removal for an action initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR Part 806.10. For example:\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>a. Your firm conducted a removal of numerous part numbers and lot numbers of your ELEOS Limb Salvage System due to sterile packaging separation and damaged trays, which can result in extended surgery time or potential patient infection. Your firm sent a Customer Notification for this issue on 6\u002F28\u002F2023. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>b. On or about 10\u002F15\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Male-Female Midsection 40MM, due to taper post misalignment, which can result in extended surgery time or improperly assembled devices leading to future disassociation. Your firm sent a Customer Notification for this issue dated 9\u002F20\u002F2024. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>c. On or about 1\u002F22\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Collar Stem, Cemented, Fluted 13MM X 120MM and Collar Stem, Cemented, Fluted 15MM X 120MM due to mislabeling of the devices, which can result in implantation or attempted implantation of an incorrect stem size, potentially extending surgery time or causing the patient to need revision surgery. Your firm sent a Customer Notification for this issue on 12\u002F22\u002F2023. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\u003C\u002Fp>\u003Cp>The adequacy of your firm’s response, dated 5\u002F14\u002F2025, regarding Observation 5 cannot be determined because we do not have assurance that your firm will make appropriate decisions following 21 CFR 806 in the future, based on your firm’s root cause stating that your firm’s SOP is ambiguous and subjective. Your firm adequately reported by retroactively submitting Reports of Correction or Removal to FDA addressing each of the three issues on 4\u002F25\u002F2025.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 712573” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Len Tokish\u003Cbr>VP of Quality Assurance &amp; Regulatory Affairs\u003Cbr>ltokish@onkossurgical.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick J. Treacy\n\nRecipient Title\n\nPresident and CEO\n\nOnkos Surgical, Inc.\n\n77 E Halsey Rd\n\nParsippany, NJ 07054\n\nUnited States\n\nptreacy@onkossurgical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 712573\nJuly 21, 2025\nDear Mr. Patrick J. Treacy:\nDuring an inspection of your firm located in Parsippany, NJ from February 4, 2025 through April 4, 2025, an investigator (or investigators) from the United States Food and Drug Administration (FDA) determined that your firm is a specification developer of the ELEOS Limb Salvage System indicated for use in total hip and knee arthroplasty for reduction or relief of pain and\u002For improved hip function in skeletally mature patients with select conditions. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Len Tokish, Vice President of Quality Assurance and Regulatory Affairs dated May 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including quality requirements, that must be met by suppliers, contractors, and consultants and define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50.\nSpecifically, you failed to adequately implement the “Approved Supplier List” section of your “Supplier, Purchasing and Inspection Controls” procedure (SOP-013; Rev. 0-6; Effective: 4\u002F25\u002F16 - 2\u002F3\u002F25) which requires that you “ensure compliance to ISO 13485” for your Tier 1 suppliers as a “method of control” over approved suppliers. For example, you did not ensure compliance to the process validation requirements (clause 7.5.6) of ISO 13485 (Medical Devices – Quality Management Systems – Requirements for regulatory purposes) for the following three (3) Tier 1 suppliers in that you failed to adequately assess and\u002For document an assessment of the acceptability of their cleaning validations meant to demonstrate that in-process or final cleaning of your ELEOS Implant Devices and Instruments consistently meet your specifications for cleanliness:\na. (b)(4) – Tier (b)(4) Final Cleaner of ELEOS Implant Devices\ni. You approved the (b)(4) cleaning validation test report TR-2771D-01 (Rev. 1-2; Approved: 1\u002F24\u002F19 and 9\u002F10\u002F21) from this supplier despite it failing to define the maximum allowable devices per gallon per run, as required by section 9.2 of the corresponding test protocol TP-2771D-01 (Rev. 2; Approved: 9\u002F10\u002F21) which states “***The main cleaning parameters that can impact the efficacy of the cleaning process include ***Quantity of parts ((b)(4))***.”\nSimilarly, you approved (b)(4) cleaning validation test report TR-2771E-01 (Rev. 1; Approved: 3\u002F18\u002F19) from this supplier despite it failing to document the maximum allowable quantity of (b)(4) and (b)(4) per run, as required by sections 9.3, 9.4, and 9.5 of the corresponding test protocol TP-2771E-01 (Rev. 1; Approved: 8\u002F28\u002F18) which state “***To validate the cleaning process, parts shall be cleaned using (b)(4) over (b)(4) runs***To create a (b)(4) batch of product***Clean what is expected to be a “(b)(4)” load in (b)(4)***A cleaning process should not alter the appearance of parts or cause damage. If applicable, appropriate fixtures to hold the components during cleaning should be included in the study and used in routine production***.”\nii. You failed to adequately assess differences in product design and geometrical configurations of candidate devices for the adoption into device families of existing (b)(4) cleaning validations conducted by this supplier because you did not accurately answer guiding questions contained in your “Assessment of Product Change or New Product Adoption for Cleaning Processes” reports. For example:\n The AC-2772-01 (Rev. 01; Effective: 7\u002F25\u002F19) and AC-277D-01 (Rev. 2; Effective: 2\u002F26\u002F21) reports show that you failed to document rationale to support your answers of “no” to the question posed in section 2 – “In relation to the existing product, does the candidate product have a similar or less complex design?” – despite the candidate devices having 4 grooves, a drive, or a male thread compared to the worst-case and comparison devices, which have none of these features.\n The AC-2772-02 report (Rev. 1; Effective: 3\u002F23\u002F20) shows that you incorrectly answered “no” to the question posed in section 2 – “In relation to the existing product, does the candidate product have fewer\u002Fsmaller or equivalent cannulated portions or lumens?” – when you compared the candidate device (segmental proximal femur, PF-2000L-02M), which has 7 cannulated holes, to the (b)(4) device ((b)(4)) and comparison devices ((b)(4)), which contain no holes.\nb. (b)(4) – Tier 1 (b)(4) Cleaner of ELEOS Implant Devices\nAlthough requested during the inspection, your Vice President of Quality Affairs and Regulatory Affairs was unable to provide documentation that you assessed the adequacy of the cleaning validations conducted in 2009 by this supplier, (b)(4). In reviewing the “Process Validation of***(b)(4) Clean Line” Operational Qualification (OQ) (E118-2116; Rev. 1; Approved: 1\u002F9\u002F09) and Performance Qualification (PQ) (E118-2116; Rev. 1; Approved: 2\u002F3\u002F09), the following deficiencies were observed:\ni. The rationale in the PQ report to accept deviations from the nominal operating range of (b)(4)°F ((b)(4), and (b)(4)°F) because OQ data showed that the process monitoring, total organic carbon (TOC), and gravimetric produced acceptable results at worst-case conditions for temperatures as low as (b)(4)°F and control charts indicated a lower control limit of (b)(4)°F (Deviation 3) does not take into account the vast differences in sample sizes ((b)(4) vs. (b)(4)) and acceptance criterion (Ppk (b)(4) vs. Ppk (b)(4)) between PQ and OQ for the same tests (TOC and gravimetric analysis) such that passing results for parameters established during OQ are not transferrable to PQ.\nii. This supplier failed to document rationale in the OQ and PQ reports for why it was acceptable to convert all negative values measured for the corrected “mass recovered from gravimetric (b)(4) and corrected “mass recovered from (b)(4) to 0.00 mg in the “Gravimetric Extraction Summary” table during gravimetric testing, thereby passing the acceptance criteria of (b)(4) mg\u002Fcm2 ((b)(4)). For example, during OQ, an (b)(4) value as high as -1.59 mg for “Hip – 4” was converted to 0.00 mg without an explanation that accounts for the possibility of testing errors, inadequate test methodology (e.g., lack of sensitivity of testing methods), and uncalibrated state of measuring equipment.\nc. (b)(4) – (b)(4) Cleaner of ELEOS Implant Devices & (b)(4) Cleaner of ELEOS Instruments\nYou approved the adoption of new products into this supplier’s existing (b)(4) cleaning validations titled “(b)(4) Cleaning Equipment & Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) and “Zenith Final Ultrasonic Cleaning Equipment & Performance Qualification Report” (FR_920-001; Rev. B; Effective: 3\u002F31\u002F15) per your Cleaning, Assembly, Packaging and Sterility (CAPS) Checklists for Project # 16-001 (Approved 10\u002F2\u002F24) and Project # 16-003 (Approved 4\u002F19\u002F24) referencing memo “(b)(4) Cleaning” (2\u002F14\u002F19) and results of a 3rd party audit conducted 2\u002F23\u002F18 despite the following deficiencies:\ni. The OQ and PQ protocols failed to require documentation of the load configurations for all work orders in that the Vice President of Quality Affairs and Regulatory Affairs was not able to determine if devices were put in a (b)(4) or broken up into (b)(4).\nii. The PQ protocol failed to include documentation of valid statistical rationale for cytotoxicity, endotoxin, and\u002For particulate testing. For example, the quantity tested per work order (66672, 66921, 66922) for cytotoxicity and endotoxin was (b)(4) and (b)(4) respectively and the quantity tested per work order (66675, 66919, 66920) for cytotoxicity, endotoxin, and particulate was (b)(4) and (b)(4), respectively.\nWe reviewed your firm’s response and concluded that it is not adequate. The immediate correction is to impose heightened controls at each supplier commensurate with risk until new worst-case cleaning validations can be completed that addresses each of the observed deficiencies for (b)(4) by 1\u002F15\u002F26, (b)(4) (target date not provided), and (b)(4) by 3\u002F1\u002F26 at the latest.\nFor (b)(4), an assessment of worst-case part justification by family was completed to establish new limits placed on (b)(4), and (b)(4). You plan to add this new loading criteria to the final DHR review by 7\u002F15\u002F25. In addition, you plan to require an update to (b)(4) internal procedure to include predicate cleaning validation review by 7\u002F15\u002F25. Based on the results of the new cleaning validation, you plan to revise top level procedures by (b)(4).\nFor (b)(4), an assessment of worst-case part justification was conducted and monitoring was put in place to control product release by assessing endotoxicity and cytotoxicity on a (b)(4) basis. In addition, you plan to require an update to this supplier’s internal procedures to improve notification of triggers to their customers by 7\u002F1\u002F25.\nFor (b)(4), you plan to conduct an assessment for worst-case part challenge per part family by (b)(4). For all instruments, interim clean line controls were implemented to require shipment of instruments to your firm and analyses of those instruments, which includes worst-case part and part family assessments prior to adoption into your clean-line part family. All parts successfully assessed will then be cleaned using your validated clean line prior to release for commercial distribution. All implants will continue to be shipped to (b)(4) for (b)(4) cleaning and will fall under controls established for therein.\nCorrective actions include updating your supplier control and design control procedures to establish minimum requirements for cleaning validations of implants and instruments, including defining key product attributes to consider when forming product families and what considerations trigger a new worst-case within a product family or new product cleaning family; creation of a procedure for part families and worst-case parts per family which defines and evaluates implant and instrument cleaning families to facilitate consistent assessment of device cleaning families across products; determination and justification of minimum sample size and attributes ((b)(4)) for validations; development of a cleaning validation checklist and modification of a supplier audit checklist that captures the aforementioned worst-case part determination, sample sizes, and minimum attributes that will be used during supplier assessment as part of design transfer and new supplier onboarding, manufacturing transfer, and supplier audit; and periodic review of validations on a scheduled interval against new standards and requirements by 6\u002F15\u002F25.\nHowever, no target date was provided for the new cleaning validation planned for (b)(4). Therefore, please provide a response regarding how you plan to address this deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, you failed to implement your Post Market Surveillance procedure (QP-18-004; Rev. 3; Effective: 6\u002F30\u002F22) which requires opening a CAPA when the (b)(4) analysis of infection complaints “***is more than (b)(4) above the literature rate or (b)(4) are above the literature rate***” for a given procedure type. For example, you did not initiate CAPAs when the (b)(4) analysis for infection complaints exceeded the rates of (b)(4)% for the distal femur ((b)(4)); (b)(4)% for proximal femur ((b)(4) and (b)(4)); and (b)(4)% for total femur ((b)(4) and (b)(4)) established in the journal article by Henderson et. al “Failure Mode Classification for Tumor Endoprostheses: Retrospective Review of Five Institutions and a Literature Review” (Journal Bone and Joint Surgery 2011) by (b)(4).\nThe adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. Under CAPA 24-011 which was initiated on 9\u002F11\u002F24 to create a more robust methodology for trending and analyzing infection related complaints, you conducted a revised retrospective assessment of (b)(4) infection rates from (b)(4) to (b)(4) (TM-25-0002; Rev. B; Approved 5\u002F14\u002F25) based on additional literature data to support updated baseline infection rates by procedure type. As a part of the corrective action, you plan to create new work instructions with requirements to perform (b)(4) trend reporting for infections and (b)(4) or (b)(4) trend reports for all other postmarket surveillance key performance indicators (KPIs); revise management review presentation slides and quality planning, postmarket surveillance, complaint handling, and CAPA procedures; and provide training on the new procedures. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to adequately establish and maintain procedures for validating the device design with regards to risk analysis, as required by 21 CFR 820.30(g).\nSpecifically, you failed to implement section 5.9 of your “Risk Management Process” procedure (SOP-008; Rev. 4-5; Effective: 3\u002F22\u002F23 - 1\u002F17\u002F25) which requires postmarket re-evaluation of risk management for a medical device as well as monitoring of postmarket information “***for assurance that no unacceptable or previously unrecognized failure modes occur. In the event of such an occurrence the potential that the residual risk or its acceptability has changed and the impact on the previously implemented risk control measures shall be evaluated***.” For example, you failed to utilize the real rate of occurrence for loosening in complaints PCR 11272023-1 ((b)(4)), PCR 05132024-1 ((b)(4)), and PCR 10172024-1 ((b)(4)) calculated at 3.27%, 0.149%, and 3.1%, respectively, to evaluate the need to update the occurrence rating in the corresponding ELEOS Stem Implant Risk Table (Project # 16-001\u002F16-003; Rev. E; Approved: 4\u002F1\u002F19), which remains unchanged at (b)(4)% through (b)(4)% since April 1, 2019.\nAn update to the postmarket rate of occurrence changes the failure mode from an acceptable risk to a conditionally acceptable risk, thereby requiring an evaluation for the need for additional risk controls and assessment for the acceptability of the residual risk as required under sections 5.6 and 5.7 of SOP-008.\nThe adequacy of the response dated 5\u002F15\u002F25 cannot be determined at this time. The immediate correction is to evaluate literature, sources, historical data, and\u002For engineering estimates against postmarket data and update the occurrence rates for the hazardous situations associated with the ELEOS Limb Salvage system by (b)(4) followed by a revision of the corresponding risk tables by (b)(4). As a part of the corrective action, you plan to revise SOP-008 to ensure that the methods used to create and maintain risk assessment tables are well-defined and create work instructions for conducting risk assessments utilizing postmarket information by (b)(4). Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n4. Failure to establish and maintain procedures for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\nSpecifically, you failed to implement section 1.1 of your “Sample Size and Statistical Techniques” procedure (SOP-014; Rev. 2-4; Effective: 8\u002F16\u002F18 - 3\u002F22\u002F23) which “***identifies valid statistical techniques that are used to establish, control and verify the acceptability of process capability and product characteristics***” pertaining to “***inspections and other analyses of objective data***” of ELEOS Implant Devices received from (b)(4). during incoming inspections. For example, your Vice President of Quality Affairs and Regulatory Affairs acknowledged that the sampling plans of the (b)(4) sampled incoming device history records (DHRs) from this supplier were not traceable to a documented valid statistical rationale.\na. You reviewed and approved incoming DHRs for Lot # (b)(4) and Lot # (b)(4) on 11\u002F2\u002F20 and 11\u002F29\u002F21 where a sampling plan of (b)(4) was used to inspect critical features during in-process inspections for which there is no documented rationale for use of this sampling plan. For example, out of (b)(4) ELEOS Tibial Baseplate Component, Size 4 (Part # TB-2204E-01M) Implant Devices, the line profile (curve) for (b)(4) each were inspected against a specification of (b)(4) at (b)(4) for Lot # (b)(4). Similarly, out of (b)(4) ELEOS Collar, 28 Diameter, Round, Porous, HA Treated (Part # HB-2800R-03M) Implant Devices, the diameter for (b)(4) each was inspected against a specification of (b)(4) at (b)(4) for Lot # (b)(4).\nb. You reviewed and approved incoming DHRs (Lot #: (b)(4)) where sampling plans utilized an AQL (acceptable quality limit) of (b)(4) or (b)(4) to inspect features during in-process and final inspections for which there are no documented rationales for use of these sampling plans. For example, out of (b)(4) ELEOS Segmental Proximal Femur, Plasma Spray, Left 98 MM (Part # PF-2000L-02M) Implant Devices, the dimensional specification of (b)(4) was inspected at an AQL level of (b)(4) for Lot # (b)(4) during final inspection on 1\u002F23\u002F24.\nWe reviewed your firm’s response and concluded that it is not adequate. The immediate corrections are to use a checklist to reassess and document rationales for acceptability of the existing AQLs selected for all contract manufactured ELEOS part families from 1\u002F1\u002F21 to 4\u002F1\u002F25 and share the rationales with the contract manufacturers by 11\u002F21\u002F25 and update SCAR 25-01 to require the contract manufacturer to include documented evidence for all inspected dimensions and associated AQL quantities by 5\u002F14\u002F25. As a part of the corrective actions, you plan to update SOP-014 and WI-013-31 (Incoming Inspection Process) to require review of incoming inspection results, consolidation of sampling procedures, set up traceable valid statistical rationales, and confirm AQLs by 7\u002F6\u002F25; update SOP-007 (Design Control) and various design transfer, manufacturing transfer, supplier, and incoming inspection checklists to include instructions for the acceptance of a supplier’s sampling procedure with confirmation of conformance to those procedures during incoming inspection of supplier DHRs by (b)(4); and develop (b)(4) inspection requirement checklists for all suppliers with a sampling procedure traceable to a valid statistical rationale based on (b)(4) by 7\u002F18\u002F25. However, these corrections and\u002For corrective actions only address the need to have a statistically valid rationale for the use of sampling plans which follow AQL and not sampling plans which utilize inspections of select critical features for the (b)(4) devices. Therefore, please provide a response on how you plan to address the above deficiency. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\nCorrections and Removals Violation(s)\nOur inspection also revealed that your firm’s ELEOS Limb Salvage System devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n5. Failure to submit a medical device Report of Correction or Removal for an action initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR Part 806.10. For example:\na. Your firm conducted a removal of numerous part numbers and lot numbers of your ELEOS Limb Salvage System due to sterile packaging separation and damaged trays, which can result in extended surgery time or potential patient infection. Your firm sent a Customer Notification for this issue on 6\u002F28\u002F2023. This action meets the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nb. On or about 10\u002F15\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Male-Female Midsection 40MM, due to taper post misalignment, which can result in extended surgery time or improperly assembled devices leading to future disassociation. Your firm sent a Customer Notification for this issue dated 9\u002F20\u002F2024. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nc. On or about 1\u002F22\u002F2024, your firm conducted a removal of your ELEOS Limb Salvage System, Collar Stem, Cemented, Fluted 13MM X 120MM and Collar Stem, Cemented, Fluted 15MM X 120MM due to mislabeling of the devices, which can result in implantation or attempted implantation of an incorrect stem size, potentially extending surgery time or causing the patient to need revision surgery. Your firm sent a Customer Notification for this issue on 12\u002F22\u002F2023. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. You did not submit a Medical Device Report of Correction or Removal to FDA for this action until after the investigation and citation.\nThe adequacy of your firm’s response, dated 5\u002F14\u002F2025, regarding Observation 5 cannot be determined because we do not have assurance that your firm will make appropriate decisions following 21 CFR 806 in the future, based on your firm’s root cause stating that your firm’s SOP is ambiguous and subjective. Your firm adequately reported by retroactively submitting Reports of Correction or Removal to FDA addressing each of the three issues on 4\u002F25\u002F2025.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 (EAT-1) Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case # 712573” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Len Tokish\nVP of Quality Assurance & Regulatory Affairs\nltokish@onkossurgical.com","Onkos Surgical, Inc.","onkos-surgical-inc-712573-07212025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fonkos-surgical-inc-712573-07212025","2026-10-26T08:09:38.140644+00:00","Warning Letter","Issued","2025-07-29","712573","Medical Devices","Patrick J. Treacy","2026-08-19T16:32:45.913+00:00","VIA Electronic Mail","2025-07-21",{"id":32,"raw":33,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":37,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},2854,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2022-02-22T14:20:00Z\">02\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-02T05:00:00Z\">02\u002F02\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmart-surgical-inc-dba-burst-biologics-614361-02022022\">Smart Surgical, Inc dba Burst Biologics\u003C\u002Fa>","Office of Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Christopher D. Jones\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Smart Surgical, Inc dba Burst Biologics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3501 W. Elder St., Ste. 104\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boise\u003C\u002Fspan>, \u003Cspan>ID\u003C\u002Fspan> \u003Cspan>83705\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 2, 2022\u003C\u002Fp>\n\n\u003Cp>[OBPO 21-614361]\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jones:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Smart Surgical, Inc., dba Burst Biologics (hereinafter, Burst Biologics), located at 3501 W. Elder St., Ste. 104, Boise, ID 83705, conducted between February 22, 2021 and March 5, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human umbilical cord blood, namely, BioBurst Fluid and BioBurst Rejuv, for allogeneic use. You distribute your products to health care providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to and during the inspection, including information on the Burst Biologics website, burstbiologics.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Burst Biologics does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from human umbilical cord blood fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” Your umbilical cord blood derived products are not intended to perform the same basic function or functions of the umbilical cord blood in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system. Rather, your products are intended to be applied to surgical and injury sites to supplement tissue defects and for orthopedic use, and your products could be administered via intra-articular injection. Using your umbilical cord blood derived products in this manner is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>In addition, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(4) because they are manufactured from allogeneic umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function, and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\u003C\u002Fp>\n\n\u003Cp>Therefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because these HCT\u002FPs do not meet all the criteria in 21 CFR 1271.10(a), and Burst Biologics does not qualify for any exception in 21 CFR 1271.15, the products are regulated as drugs as defined in section 201(g) of the FD&amp;C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your HCT\u002FPs derived from human umbilical cord blood are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Part 1271. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant deviations from CGMP and CGTP requirements applicable to your products. These deficiencies include, but are not limited to, the following:\u003Cbr>\n\u003Cbr>\n\u003Cstrong>1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)].\u003C\u002Fstrong> FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent or disease (RCDAD) under 21 CFR 1271.3(r)(2). Since ZIKV is a RCDAD, donors of umbilical cord, blood, placenta or other gestational tissues should be considered ineligible if certain risk factors are present. However, in May 2016, you began receiving umbilical cord blood units recovered from allogeneic donors in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an area considered at increased risk for ZIKV, and you failed to determine these donors as ineligible. These umbilical cord blood units were manufactured into BioBurst Fluid and BioBurst Rejuv and distributed throughout the United States. Although you have since developed new procedures that provide for assessing eligibility based on ZIKV, your prior deficiencies raise potentially significant safety concerns.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)].\u003C\u002Fstrong> Your firm failed to adequately validate the aseptic process used to manufacture BioBurst Fluid and BioBurst Rejuv (i.e., by performing media fill simulations) since manufacturing began in December 2015. Since then, your firm manufactured and distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of BioBurst Fluid and BioBurst Rejuv. These products purport to be sterile. More specifically:\u003C\u002Fp>\n\n\u003Cp>a. Prior to October 31, 2019, you did not conduct any media fill simulations to validate the aseptic manufacturing process for BioBurst Fluid and BioBurst Rejuv to demonstrate that your aseptic process can consistently produce products free of viable microorganisms.\u003C\u002Fp>\n\n\u003Cp>b. On October 31, 2019, a validation plan (VAL-PR-UCB Product Manufacturing-003) under which media fill simulations were conducted to validate your aseptic process for BioBurst Fluid and BioBurst Rejuv was approved; however, the media fills performed under this plan are inadequate\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. For example, the units produced during your media fill simulations were not incubated under conditions adequate to detect microorganisms that might otherwise be difficult to culture. Media fill samples were only incubated for \u003Cstrong>(b)(4)\u003C\u002Fstrong> days.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)].\u003C\u002Fstrong> Your firm has not established an adequate system for environmental, including personnel, monitoring in the aseptic processing areas where BioBurst Fluid and BioBurst Rejuv are manufactured. For example:\u003C\u002Fp>\n\n\u003Cp>a. Your firm does not investigate personnel monitoring excursions that exceed your action limit. Approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of product associated with personnel monitoring excursions that were not investigated were distributed since October 2020.\u003C\u002Fp>\n\n\u003Cp>b. Your environmental monitoring procedure describes that up to and including \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>colony forming units (CFUs) is an acceptable result for a single personnel monitoring sample, including a sample from glove fingertips that enter the ISO-5 classified biological safety cabinet (BSC) where aseptic processing is conducted. We note that the current industry standard is &lt;1 CFU\u002Fplate for gloves or sleeves that enter the ISO-5 classified area and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for gowning that remains in the ISO-7 classified area. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potential significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf\u003C\u002Fa>. FDA’s guidance documents do not establish legal requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)].\u003C\u002Fstrong> Specifically, you told our investigator that components utilized within UCB (umbilical cord blood) manufacturing are not sampled and tested prior to being used in production.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192].\u003C\u002Fstrong> Specifically, since December 2015, your firm has had numerous sterility failures for batches of BioBurst Fluid and BioBurst Rejuv that you failed to investigate to determine the source of the contamination beyond identifying organisms (for example, a \u003Cem>Paenibacillus\u003C\u002Fem> species, \u003Cem>Bacillus\u003C\u002Fem> non-anthracis, \u003Cem>Kocuria rhizophila\u003C\u002Fem>,&nbsp;\u003Cem>Staphylococcus hominis\u003C\u002Fem>, and \u003Cem>Micrococcus luteus\u003C\u002Fem>) for a subset of these failed batches. For over 80% of the failures, you did not identify the contaminating microorganism(s). Since December 2015, your firm manufactured and distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of BioBurst Fluid and BioBurst Rejuv.\u003C\u002Fp>\n\n\u003Cp>In addition to the above violations, we also note that we are concerned that you may not have verified the suitability of your sterility test method, that you represent is based on USP &lt;71&gt;, used for final product release testing of BioBurst Fluid and BioBurst Rejuv batches from December 2015 until July 31, 2020. Numerous BioBurst Fluid and BioBurst Rejuv batches remain within expiry. Please be reminded that you are required to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods employed, in accordance with 21 CFR 211.165(e).\u003Cbr>\n\u003Cbr>\nWe acknowledge receipt of your correspondences, dated April 16, 2021 and May 14, 2021, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. The responses to many of the observations do not provide sufficient detail to fully assess the adequacy of your corrective actions to date, lack a timeline for completion of all necessary corrective actions, and lack documentation to demonstrate that you have corrected your violations. Additionally, your responses are unsatisfactory in that they do not address your firm’s manufacture and distribution of your products derived from umbilical cord blood under the violative conditions outlined above. Nor do your responses remedy the above-noted violations.\u003C\u002Fp>\n\n\u003Cp>While you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Amy Graf, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>cc\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>_______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We also found no indication that the media used in your media fill simulation was demonstrated to promote growth of organisms pre- or post-incubation of media-filled units. Growth promotion of each batch of media should be performed to demonstrate the media is capable of detecting microorganisms. Furthermore, the October 2019 study was the only executed media fill simulation provided to FDA during the inspection. We recommend that routine media fill simulations be conducted semi-annually to evaluate the state of control of the aseptic process.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMr. Christopher D. Jones\n\nRecipient Title\n\nChief Executive Officer\n\nSmart Surgical, Inc dba Burst Biologics\n\n3501 W. Elder St., Ste. 104\n\nBoise, ID 83705\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWARNING LETTER\n\nFebruary 2, 2022\n\n[OBPO 21-614361]\n\nDear Mr. Jones:\n\nDuring an inspection of your firm, Smart Surgical, Inc., dba Burst Biologics (hereinafter, Burst Biologics), located at 3501 W. Elder St., Ste. 104, Boise, ID 83705, conducted between February 22, 2021 and March 5, 2021, the United States Food and Drug Administration (FDA) documented that you manufacture products derived from human umbilical cord blood, namely, BioBurst Fluid and BioBurst Rejuv, for allogeneic use. You distribute your products to health care providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered prior to and during the inspection, including information on the Burst Biologics website, burstbiologics.com, reflect that your products are intended to treat various diseases or conditions. Therefore, these products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour products are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBurst Biologics does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FPs derived from human umbilical cord blood fail to meet all the criteria in 21 CFR 1271.10(a).\n\nSpecifically, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” Your umbilical cord blood derived products are not intended to perform the same basic function or functions of the umbilical cord blood in the recipient as in the donor, such as forming and replenishing the lymphohematopoietic system. Rather, your products are intended to be applied to surgical and injury sites to supplement tissue defects and for orthopedic use, and your products could be administered via intra-articular injection. Using your umbilical cord blood derived products in this manner is not homologous use as defined in 21 CFR 1271.3(c).\n\nIn addition, your umbilical cord blood derived products fail to meet the criterion in 21 CFR 1271.10(a)(4) because they are manufactured from allogeneic umbilical cord blood, are dependent on the metabolic activity of living cells for their primary function, and are not for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.\n\nTherefore, these HCT\u002FPs are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Because these HCT\u002FPs do not meet all the criteria in 21 CFR 1271.10(a), and Burst Biologics does not qualify for any exception in 21 CFR 1271.15, the products are regulated as drugs as defined in section 201(g) of the FD&C Act [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the PHS Act [42 U.S.C. 262(i)].\n\nPlease be advised that to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. Your HCT\u002FPs derived from human umbilical cord blood are not the subject of an approved biologics license application (BLA) nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) and current good tissue practice (CGTP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Part 1271. The deviations in manufacturing observed, as well as those noted in documents collected during the inspection, indicate that the use of your products raises potential significant safety concerns. For example, your deficient donor screening practices, inadequate aseptic practices, unvalidated manufacturing processes, and deficient environmental monitoring, as described below, pose a significant risk that your products may be contaminated with microorganisms or have other serious product quality defects.\n\nAt the close of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described a number of significant deviations from CGMP and CGTP requirements applicable to your products. These deficiencies include, but are not limited to, the following:\n\n1. Failure to determine as ineligible a donor who is identified as having a risk factor for, or clinical evidence of, any of the relevant communicable disease agents or diseases for which screening is required under 21 CFR 1271.75(a)(1) [21 CFR 1271.75(d)(1)]. FDA has identified Zika virus (ZIKV) as a relevant communicable disease agent or disease (RCDAD) under 21 CFR 1271.3(r)(2). Since ZIKV is a RCDAD, donors of umbilical cord, blood, placenta or other gestational tissues should be considered ineligible if certain risk factors are present. However, in May 2016, you began receiving umbilical cord blood units recovered from allogeneic donors in (b)(4), an area considered at increased risk for ZIKV, and you failed to determine these donors as ineligible. These umbilical cord blood units were manufactured into BioBurst Fluid and BioBurst Rejuv and distributed throughout the United States. Although you have since developed new procedures that provide for assessing eligibility based on ZIKV, your prior deficiencies raise potentially significant safety concerns.\n\n2. Failure to establish appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. Your firm failed to adequately validate the aseptic process used to manufacture BioBurst Fluid and BioBurst Rejuv (i.e., by performing media fill simulations) since manufacturing began in December 2015. Since then, your firm manufactured and distributed approximately (b)(4) units of BioBurst Fluid and BioBurst Rejuv. These products purport to be sterile. More specifically:\n\na. Prior to October 31, 2019, you did not conduct any media fill simulations to validate the aseptic manufacturing process for BioBurst Fluid and BioBurst Rejuv to demonstrate that your aseptic process can consistently produce products free of viable microorganisms.\n\nb. On October 31, 2019, a validation plan (VAL-PR-UCB Product Manufacturing-003) under which media fill simulations were conducted to validate your aseptic process for BioBurst Fluid and BioBurst Rejuv was approved; however, the media fills performed under this plan are inadequate1. For example, the units produced during your media fill simulations were not incubated under conditions adequate to detect microorganisms that might otherwise be difficult to culture. Media fill samples were only incubated for (b)(4) days.\n\n3. Failure to have an adequate system for monitoring environmental conditions in an aseptic processing area necessary to prevent contamination or mixups [21 CFR 211.42(c)(10)(iv)]. Your firm has not established an adequate system for environmental, including personnel, monitoring in the aseptic processing areas where BioBurst Fluid and BioBurst Rejuv are manufactured. For example:\n\na. Your firm does not investigate personnel monitoring excursions that exceed your action limit. Approximately (b)(4) units of product associated with personnel monitoring excursions that were not investigated were distributed since October 2020.\n\nb. Your environmental monitoring procedure describes that up to and including (b)(4) colony forming units (CFUs) is an acceptable result for a single personnel monitoring sample, including a sample from glove fingertips that enter the ISO-5 classified biological safety cabinet (BSC) where aseptic processing is conducted. We note that the current industry standard is \u003C1 CFU\u002Fplate for gloves or sleeves that enter the ISO-5 classified area and (b)(4) for gowning that remains in the ISO-7 classified area. Your allowance for such high numbers of microorganisms could contribute to product contamination and pose a potential significant safety concern. For additional information, we recommend that you review FDA Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice, available at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidances\u002Fucm070342.pdf. FDA’s guidance documents do not establish legal requirements.\n\n4. Failure to withhold from use each lot of components, drug product containers, and closures until the lot has been sampled, tested, or examined, as appropriate, and released for use by the quality control unit [21 CFR 211.84(a)]. Specifically, you told our investigator that components utilized within UCB (umbilical cord blood) manufacturing are not sampled and tested prior to being used in production.\n\n5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed [21 CFR 211.192]. Specifically, since December 2015, your firm has had numerous sterility failures for batches of BioBurst Fluid and BioBurst Rejuv that you failed to investigate to determine the source of the contamination beyond identifying organisms (for example, a Paenibacillus species, Bacillus non-anthracis, Kocuria rhizophila, Staphylococcus hominis, and Micrococcus luteus) for a subset of these failed batches. For over 80% of the failures, you did not identify the contaminating microorganism(s). Since December 2015, your firm manufactured and distributed approximately (b)(4) units of BioBurst Fluid and BioBurst Rejuv.\n\nIn addition to the above violations, we also note that we are concerned that you may not have verified the suitability of your sterility test method, that you represent is based on USP \u003C71>, used for final product release testing of BioBurst Fluid and BioBurst Rejuv batches from December 2015 until July 31, 2020. Numerous BioBurst Fluid and BioBurst Rejuv batches remain within expiry. Please be reminded that you are required to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods employed, in accordance with 21 CFR 211.165(e).\n\nWe acknowledge receipt of your correspondences, dated April 16, 2021 and May 14, 2021, responding to FDA’s inspectional observations on the FDA-483. We have reviewed the corrective actions outlined in the response, and we have determined that the response is inadequate to address our concerns. The responses to many of the observations do not provide sufficient detail to fully assess the adequacy of your corrective actions to date, lack a timeline for completion of all necessary corrective actions, and lack documentation to demonstrate that you have corrected your violations. Additionally, your responses are unsatisfactory in that they do not address your firm’s manufacture and distribution of your products derived from umbilical cord blood under the violative conditions outlined above. Nor do your responses remedy the above-noted violations.\n\nWhile you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such a product may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nNeither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies that may exist at your facility. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTATRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Amy Graf, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 300 River Place Drive, Suite 5900, Detroit, MI 48207 or emailed to Amy.Graf@fda.hhs.gov. If you have any questions, please contact Amy Graf, Compliance Officer at (313) 393-2034 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\ncc\n\n(b)(6)\n\n_______________________________\n\n1 We also found no indication that the media used in your media fill simulation was demonstrated to promote growth of organisms pre- or post-incubation of media-filled units. Growth promotion of each batch of media should be performed to demonstrate the media is capable of detecting microorganisms. Furthermore, the October 2019 study was the only executed media fill simulation provided to FDA during the inspection. We recommend that routine media fill simulations be conducted semi-annually to evaluate the state of control of the aseptic process.","Smart Surgical, Inc dba Burst Biologics","smart-surgical-inc-dba-burst-biologics-614361-02022022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsmart-surgical-inc-dba-burst-biologics-614361-02022022","2026-10-26T08:09:59.293166+00:00","2022-02-22","614361","Biologics","Mr. Christopher D. Jones","2026-08-20T02:09:59.584+00:00","VIA UNITED PARCEL SERVICE","2022-02-02",2,{"510k":56,"classification":57,"enforcement":58,"event":59,"event_backfill":60,"pma":61,"warning_letter":62},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]